Skip to main content
BioCentury Conference Center

SciBX Summit 2013 Program/Schedule

  The 2013 SciBX Summit will be held on October 30 at The Colonnade Hotel in Boston, MA. An overview of the topics to be presented appears below.

When you register online, you will be prompted to select one of the two concurrent panel presentations in Session I and Session II.

Organized by


Nature Publishing Group

2013 Sponsors
2013 Sponsors
2013 Advisory
Council Members

2013 Advisory Council
  Schedule of Events
For a schedule of events, please download a PDF of the program: Download program
Session I – (Oct. 30; 9:00 a.m. – 12:00 p.m.) Concurrent Sessions

Non-Coding RNAs as Tools and Targets

  Over the past decade, the discovery of thousands of noncoding RNAs, including numerous microRNAs, long noncoding RNAs, and more recently circular RNAs, has opened new opportunities to develop therapeutics and diagnostics that harness or target these molecules in indications ranging from cardiovascular disease to cancer. This has contributed to a robust commercial landscape, but fundamental translational issues remain, ranging from the need for better understanding of the role of noncoding RNAs in disease mechanisms and their druggability, to drug development challenges including stability and delivery. This SciBX Summit session will examine these challenges and offer solutions for progress.

New Models in Neurological Diseases

  Over the past three decades, promising neurological leads identified through a combination of computational approaches, in vitro systems and animal models have mostly failed in Phase II or Phase III clinical trials. This failure of clinical translation has prompted many companies to abandon the CNS space, highlighting the urgent need for better cell-based and animal models. This SciBX Summit session will lay out the necessary next steps to reinvigorate the field, focusing on changing paradigms in schizophrenia, autism and depression. Panelists will discuss the challenges of developing new animal models in these fields, and the potential of iPS cells and novel imaging technologies to lead to increased success rates in CNS drug development.
  Session II – (Oct. 30; 2:00 p.m. – 5:00 p.m.) Concurrent Topics
Program CAR-Based Cellular Therapies
  Chimeric antigen receptor (CAR)-based cell therapies burst onto the scene in 2011 when clinical results from three CLL patients showed impressive efficacy. What has followed is a spate of licensing activity, as companies such as Novartis and Celgene have struck deals with academic institutions developing CAR-based therapies. Despite their promise, CAR-based approaches still face a host of obstacles on the way to full implementation. This SciBX Summit session will outline a roadmap for improving the safety profile of the engineered cells, scaling up their manufacture, determining whether they can be used in solid tumors in addition to blood cancers, and determining tumor mutation rates, which could affect long-term efficacy of the therapies.
Program Epigenetics' Second Wind
  The number of preclinical programs and deals in the epigenetics space has exploded in recent years, with many companies pursuing inhibitor programs for several histone methyltransferases (HMTs) and BET bromodomains for cancer. But beyond these first generation targets, there are novel HMT and bromodomain targets emerging as well as initial reports on druggable histone demthylases, in cancer and in other indications, that herald a potential second wave of development in the space. Preclinical challenges include the basic question of how best to match epigenetic targets with particular disease indications – whether to base it on genetic alterations in protein coding regions of the genome or in regulatory ones – and on the practical side there are also challenges in developing assays to screen epigenetic inhibitors. This SciBX Summit session will examine these challenges and outline the steps for overcoming them.